Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Frovatriptan.

S E Easthope1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|December 12, 2001
PubMed
Summary
This summary is machine-generated.

Frovatriptan effectively treats acute migraine with a single 2.5mg dose, offering rapid relief and reducing recurrence. This serotonin receptor agonist demonstrated good tolerability in clinical trials for migraine management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Follitropin alpha in infertility: a review.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Trials

Background:

  • Frovatriptan is a novel serotonin receptor agonist designed for acute migraine treatment.
  • It exhibits high affinity for serotonin 5-HT1B and 5-HT1D receptor subtypes.
  • Frovatriptan stimulates contraction in human basilar arteries.

Purpose of the Study:

  • To evaluate the efficacy and safety of frovatriptan for the acute treatment of migraine.
  • To assess the pharmacokinetic profile of frovatriptan, particularly its elimination half-life.
  • To determine the impact of frovatriptan on migraine symptom relief and recurrence.

Main Methods:

  • Clinical trials were conducted involving patients with acute migraine.
  • A single oral dose of frovatriptan 2.5mg was administered and compared against placebo.

Related Experiment Videos

  • Pharmacokinetic parameters, including elimination half-life, were analyzed.
  • Adverse events were recorded and compared between frovatriptan and placebo groups.

    • Main Results:

    • A single 2.5mg oral dose of frovatriptan provided meaningful migraine relief within 2 hours for approximately twice as many patients as placebo.
    • Consistent symptom relief was observed in patients treating consecutive migraine attacks.
    • The incidence of 24-hour migraine recurrence was reduced with frovatriptan use.
    • Frovatriptan exhibited a long terminal elimination half-life of approximately 26 hours, independent of demographic and renal factors.
    • The overall incidence of adverse events with frovatriptan 2.5mg was only slightly higher than placebo, with mild to moderate fatigue, nausea, and paresthesia being most common.

    Conclusions:

    • Frovatriptan 2.5mg is an effective treatment for the acute management of migraine.
    • The drug offers a favorable pharmacokinetic profile with a long half-life.
    • Frovatriptan is well-tolerated and demonstrates potential in reducing migraine recurrence.